knowledge -WSS

knowledge

author：explore 2025-10-02 14:22:39 - browse：42579

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

hotspot

WSS

AI can decode, harness the power of the humane immune system

Nearly two

What to expect at HLTH 2023, the health care industry conference

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

Why Charlie Gard's case is so disturbing to Americans

Stroke deaths set to near 10 million globally by 2050

leisure time

knowledge

hotspot

Virginia high school admissions case could be legal follow

A cyberattack has disrupted hospitals and health care in several states

After affirmative action ruling, medical educators look to 'holistic review'

OTC birth control: A brief history of over the counter pill design

The high cost of giving birth even with insurance

Microsoft strikes partnership with Duke Health to advance health AI

Duchenne breakthrough therapy leaves behind pioneering families

ER docs worry over extreme heat as a 'mass casualty event'

Moonlake's readout produced a cash windfall. Risks remain

Attacks on the drug industry will lead to fewer breakthroughs

hotspot

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

Sana to lay off nearly a third of staff, de

When women are denied an abortion, their children fare worse than peers

FDA authorizes Novavax’s updated Covid

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

Was Amgen transparent enough on FDA's concern on cancer drug?

entertainment

hotspot

hotspot

hotspot